ORTEQ Sports Medicine, **founded in 2005**, aims to address meniscus and articular cartilage injuries through regenerative joint preservation solutions. The company's **Actifit** implant enables the regeneration of meniscus defects, offering significant potential to enhance joint health and delay the need for full meniscus replacement, providing pain relief and functional improvement for up to 10 years. Additionally, **CartiONE** offers unique cartilage repair technology employing endogenous chondrocytes in a single surgery. With **products validated in over 30 peer-reviewed clinical publications and cited in over 100 journal articles**, ORTEQ's innovations have gained international recognition, with Actifit available in **more than 30 countries**. The company received its **Venture Round investment from Kensey Nash Corporation on 08 January 2011**. Headquartered in the **United Kingdom**, ORTEQ operates at the intersection of biotechnology, healthcare, manufacturing, and sports industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 | Kensey Nash Corporation | 08 Jan 2011 |
| Series B | £8.00M | 1 |
|
07 Oct 2008 |
No recent news or press coverage available for ORTEQ Sports Medicine.
We care about your data, and we'd love to use cookies make your experience better.
